616 related articles for article (PubMed ID: 34557660)
1. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
3. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
[TBL] [Abstract][Full Text] [Related]
4. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
5. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
Wu X; Li P; Mi YQ
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
[No Abstract] [Full Text] [Related]
7. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.
Yoon JS; Lee HY; Chung SW; Kim SW; Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim H; Yoon JH; Kim YJ
J Gastroenterol Hepatol; 2020 Nov; 35(11):1960-1968. PubMed ID: 32128882
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
10. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.
Choi HSJ; Brouwer WP; Zanjir WMR; de Man RA; Feld JJ; Hansen BE; Janssen HLA; Patel K
Hepatology; 2020 Feb; 71(2):539-548. PubMed ID: 31309589
[TBL] [Abstract][Full Text] [Related]
13. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
14. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
15. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
16. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.
Lee YB; Ha Y; Chon YE; Kim MN; Lee JH; Park H; Kim KI; Kim SH; Rim KS; Hwang SG
Clin Mol Hepatol; 2019 Mar; 25(1):52-64. PubMed ID: 30360031
[TBL] [Abstract][Full Text] [Related]
17. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
18. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
19. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
20. Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up.
Lim CT; Goh GBB; Li H; Lim TK; Leow WQ; Wan WK; Azhar R; Chow WC; Kumar R
Microbiol Insights; 2020; 13():1178636120918878. PubMed ID: 32435130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
